Table 2.
Parameter | Placebo | Exenatide | L‐NMMA | Exenatide/L‐NMMA |
---|---|---|---|---|
HR (beats min −1 ) | 58.3 (52.6–63.9) | 63.6 (57.5–69.6) | 53.4 (48.8–57.9) | 59.6 (52.9–66.6) |
SBP (mmHg) | 112.7 (104.2–121.2) | 118.7 (112.7–124.7) | 119.0 (109.2–128.8) | 125.2 (119.0–131.4) |
DBP (mmHg) | 66.2 (61.3–71.1) | 63.6 (59.9–67.3) | 73.7 (67.5–79.9) | 73.9 (69.6–78.1) |
MAP (mmHg) | 82.2 (75.9–88.4) | 83.8 (80.0–87.6) | 89.5 (83.1–95.9) | 92.1 (88.7–95.4) |
SV (ml) | 114.2 (103.4–125.0) | 119.8 (109.5–130.1) | 115.7 (110.4–120.9) | 121.9 (112.2–131.5) |
CO (l min −1 ) | 6.8 (6.4–7.3) | 7.9 (7.0–8.8) | 6.5 (5.7–7.3) | 7.8 (7.2–8.4) |
TPR (dyns·s cm −5 ) | 1001.5 (847.4–1155.6) | 971.8 (817.4–1126.2) | 1162.8 (1035.6–1289.9) | 983.2 (898.4–1067.9) |
RPP (mmHg * beats min −1 ) | 6632.5 (5611.9–7653.1) | 7576.2 (6638.7–8513.6) | 6392.1 (5515.6–7268.6) | 7502.7 (6500.3–8505.1) |
LF : HF ratio * | N/A | 1.86 [0.65–4.79] | N/A | 1.56 [0.85–3.21] |
Glucose (mmol l −1 ) | 4.24 (4.14–4.35) | 3.68 (3.54–3.82) | 4.40 (4.07–4.73) | 3.80 (3.69–3.92) |
Insulin (pmol l −1 ) * | 28.8 [21.8–52.8] | 30.6 [20.5–49.2] | 24.5 [17.6–34.2] | 27.8 [18.9–42.7] |
All values represent the variables after 90 min infusion of placebo, exenatide, L‐NMMA and exenatide/L‐NMMA.
non‐Gaussian distribution, thus median [IQR] are shown. CO, cardiac output; DBP, diastolic blood pressure; HR, heart rate; LF : HF ratio, low frequency to high frequency ratio; L‐NMMA, L‐NG‐monomethyl‐arginine‐citrate; MAP, mean arterial pressure; N/A, not available; RPP, rate‐pressure product; SBP, systolic blood pressure; SV, stroke volume; TPR, total peripheral resistance.